Emerging mitotic inhibitors for non-small cell carcinoma.
Napoli, Italy. In Expert Opin Emerg Drugs, 31 Mar 2013
Furthermore, the identification of novel mitotic drug targets other than microtubules has gained recently much attention, such as aurora kinases, Polo-like kinase1 (PLK1), kinesin spindle protein (KSP), and centromeric protein E (CENPE).
Regulatory mechanisms and clinical perspectives of miRNA in tumor radiosensitivity.
Changsha, China. In Carcinogenesis, Nov 2012
Moreover, the regulatory effect of miRNA in radiosensitivity can be enhanced when interacting with various key molecules, including H2AX, BRCA1, ATM, DNA-PK, RAD51, Chk1, Cdc25A, p53, PLK1, HIF-1 and VEGF, which are involved in these processes.
A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets.
Oss, Netherlands. In Br J Pharmacol, Jun 2012
In addition, we recommend which inhibitors to use for studying the biology of the 20 most investigated kinases that are clinically relevant: Abl (ABL1), AKT1, ALK, Aurora A/B, CDKs, MET, CSF1R (FMS), EGFR, FLT3, ERBB2 (HER2), IKBKB (IKK2), JAK2/3, JNK1/2/3 (MAPK8/9/10), MEK1/2, PLK1, PI3Ks, p38α (MAPK14), BRAF, SRC and VEGFR2 (KDR).
Shared and separate functions of polo-like kinases and aurora kinases in cancer.
More papers using
Utrecht, Netherlands. In Nat Rev Cancer, 2010
Within the polo-like kinase family, the emphasis for targeted therapies has been on polo-like kinase 1 (PLK1), and in the aurora kinase family drugs have been developed to specifically target aurora kinase A (AURKA; also known as STK6) and/or aurora kinase B (AURKB; also known as STK12).
Host-pathogen interactions: leukocyte phagocytosis and associated sequelae
In Cell Death & Disease, 2001
... anti-SR-A (clone SRA-E5, Trans Genic Inc., Kobe, Japan) and anti-LOX-1, anti-MARCO and anti-CD36 (clones 23C11, PLK1 and FA6-152, respectively, Cell Sciences, Canton, MA, USA) ...